Pharmaceutical Technology

JUNE 7, 2023

Baudax Bio revealed has additional results from a Phase II trial investigating its neuromuscular blockade (NMD) agent BX1000 in patients undergoing elective surgery demonstrating favourability to rocuronium. BX1000 is an intermediate duration, clinical-stage blocking agent. mg/kg administered intravenously.

Clinical Trials 130

Clinical Trials Clinical Trials Licensing Licensing 130

Drug Discovery World

JUNE 9, 2023

News round-up for 5-9 June by DDW Digital Content Editor Diana Spencer. The top stories: Successful Phase I results for cardioprotective drug Serca Pharmaceuticals has presented data on a novel approach to modulate the beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility.

Clinical Trials 52

Clinical Trials Clinical Trials Drugs Trials 52

Drug Discovery World

MARCH 10, 2023

News round-up for 6-10 March by DDW Digital Content Editor Diana Spencer. Perhaps most interestingly this week, after previous caution over in vivo gene therapy trials, the FDA has given the go ahead to Intellia Therapeutics to study NTLA-2002 in hereditary angioedema (HAE).

In-Vivo 52

In-Vivo Clinical Trials Clinical Trials Drugs 52

Drug Discovery World

JANUARY 26, 2024

News round-up for 22-26 January by DDW Digital Content Editor Diana Spencer. Phase IIa trial launches in advanced pancreatic cancer The Phase IIa ACCENT trial has launched to explore the activity of focal adhesion kinase (FAK) inhibitor narmafotinib in combination with standard-of-care chemotherapy in advanced pancreatic cancer patients.

Drugs 52

Drugs Trials Research Development 52

XTalks

FEBRUARY 20, 2024

Safety assessments of sibeprenlimab have revealed no evidence of adverse toxic effects or clinically significant immunosuppression. At month 12, the percentage of patients achieving clinical remission was 7.9 How Does Sibeprenlimab Work? percent (three of 38 patients), 12.2 percent (five of 41 patients), 26.3

Clinical Trials 59

Clinical Trials Clinical Trials FDA Approval Trials 59

Drug Discovery World

SEPTEMBER 22, 2023

News round-up for 18-22 September by DDW Digital Content Editor Diana Spencer. UK scientists prepare for Nipah virus clinical trial The University of Oxford has revealed that researchers are currently in the advanced stages of preparing for a clinical trial of a Nipah vaccine using the ChAdOx1 vector.

Drugs 52

Drugs Vaccination Vaccine Clinical Trials 52

Drug Discovery World

JANUARY 15, 2024

The announcement follows the news that Merck agreed a deal with Inspirna for colorectal cancer drug ompenaclid (RGX-202). “At This agreement reflects the creativity and commitment of scientists and clinical development teams at Harpoon. The study is also evaluating HPN328 in combination with atezolizumab in patients with SCLC.

Clinical Development 105

Clinical Development Clinical Trials Clinical Trials Development 105

Drug Discovery World

JUNE 2, 2023

News round-up for 29 May – 2 June by DDW Digital Content Editor Diana Spencer. With National Cancer Research Month coming to an end and the American Society of Clinical Oncology Annual Meeting currently taking place in Chicago (2-6 June), it’s been another busy week for cancer drug development news.

Drugs 52

Drugs HR Antibody Clinical Trials 52

Pharmaceutical Technology

DECEMBER 23, 2022

This approval is backed by findings from the multicentre, double-blinded, placebo-controlled, international Phase II/III CAPELLA clinical trial of lenacapavir plus an optimised background regimen. Subcutaneous lenacapavir’s antiviral activity administered every six months was analysed in the trial.

Drugs 147

Drugs FDA Approval Clinical Trials Clinical Trials 147

Pharmaceutical Technology

SEPTEMBER 23, 2022

More than double the volume of Fennec’s shares were traded on the day of the approval news in comparison to 19 September. Pedmark clinical trials. Fennec Pharmaceuticals assessed Pedmark in the two multicentre clinical trials SIOPEL 6 (NCT00652132) and COG ACCL0431 (NCT00716976).

Drugs 130

Drugs FDA Approval Clinical Trials Clinical Trials 130

Drug Discovery World

NOVEMBER 3, 2023

News round-up for 30 October – 3 November by DDW Editor Reece Armstrong My news highlights this week feature a variety of exciting clinical trial results and launches that are examining therapies for much-needed disease areas, new drug approvals and even a space mission with a pharma twist.

Drugs 52

Drugs Gene Therapy Clinical Trials Clinical Trials 52

Drug Discovery World

MARCH 24, 2023

News round-up for 20-24 March by DDW Digital Content Editor Diana Spencer. There have also been positive trial results announced in prostate cancer, pancreatic cancer and breast cancer. This week we have seen a number of developments in the treatment of solid tumours hitting the headlines.

Drugs 52

Drugs Hormones Trials Research 52

Drug Discovery World

NOVEMBER 1, 2023

Durvalumab and olaparib, AstraZeneca A primary analysis of the DUO-E Phase III trial investigating durvalumab and olaparib in advanced or recurrent endometrial cancer showed an improvement in PFS compared to chemotherapy, reducing the risk-of disease progression or death by 45%. months for amivantamab plus chemotherapy vs. 6.7

Clinical Trials 59

Clinical Trials Clinical Trials Trials HR 59

Drug Discovery World

AUGUST 11, 2023

News round-up for by DDW Digital Content Editor Diana Spencer. The news headlines this week reflect the level of interest in cell & gene therapies (CGT) in the sector, particularly CAR-T, but also the importance of research collaborations to bring these therapies to patients.

Gene Therapy 52

Gene Therapy Drugs Clinical Trials Clinical Trials 52

Drug Discovery World

JANUARY 23, 2023

Clinical trials have led our news section this week, with positive results announced from several Phase I and II studies. There was good news from Alto Neuroscience, everImmune, Avacta and Abionyx, though unfortunately things are not looking so rosy for Janssen’s HIV vaccine candidate.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Drug Discovery World

AUGUST 12, 2022

News round-up by DDW’s Reece Armstrong for 8-12 August . New insights into melanoma, a company transition into life sciences and a Lyme disease vaccine are some of the stories in this week’s news round-up. Pfizer launches Phase III trial for Lyme disease vaccine?? .

Life Science 52

Life Science Drugs Vaccination Vaccine 52

XTalks

FEBRUARY 19, 2024

The team used the data and patient samples from a gB/MF59 Phase II trial in adolescent girls as a benchmark to assess the new mRNA-based vaccine. The comparison is particularly important as gB/MF59 demonstrated promise in Phase II clinical trials but did not advance to Phase III.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Drug Discovery World

JULY 24, 2023

The most impactful drug discovery news this week is all linked with scientific research data. Analysts Phesi revealed that a third of clinical development programmes are cancelled during Phase II, and there were significant trial results for drugs for head and neck cancer and Alzheimer’s disease.

Clinical Development 52

Clinical Development Gene Scientist Trials 52

Drug Discovery World

JULY 24, 2023

The most impactful drug discovery news this week is all linked with scientific research data. Analysts Phesi revealed that a third of clinical development programmes are cancelled during Phase II, and there were significant trial results for drugs for head and neck cancer and Alzheimer’s disease.

Clinical Development 52

Clinical Development Gene Scientist Drugs 52

Drug Discovery World

DECEMBER 22, 2023

News round-up for 18-22 December by DDW Digital Content Editor Diana Spencer. There have been some ground-breaking advances in women’s health this week, with new treatments for hot flushes and pregnancy sickness, and a discovery that could aid in development of treatments for secondary breast cancer.

Drugs 52

Drugs Antibody FDA Approval Clinical Trials 52

XTalks

MAY 31, 2023

Headquartered in California, Acelyrin is a late-stage clinical biopharmaceutical company dedicated to expediting the development and delivery of groundbreaking medicines in the field of immunology. The success of Acelyrin can be attributed to its industry-leading immunology portfolio and a robust pipeline of clinical and preclinical programs.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Production 97

XTalks

JULY 17, 2023

“Astellas is committed to bringing innovative therapies to patients with hard-to-treat cancers, including gastric cancer,” said Moitreyee Chatterjee-Kishore, senior vice president and head of immuno-oncology development at Astellas, in the news release. In both trials, approximately 38 percent of the screened patients had CLDN18.2-positive

Clinical Trials 95

Clinical Trials Clinical Trials Trials Antibody 95

Drug Discovery World

AUGUST 4, 2023

News round-up for 31 July – 4 August by DDW Digital Content Editor Diana Spencer. These include the creation of a compound that can block the spread of cancer and the discovery that PARP inhibitors could be effective in a new group of patients.

Drugs 52

Drugs RNA Gene Scientist 52

BioTech 365

DECEMBER 22, 2020

DGAP-News: Apogenix AG / Key word(s): Study 22.12.2020 / 10:00 The issuer is solely responsible for the content of this announcement. COVID-19: targeted treatment trial launched in Vienna (Vienna/Heidelberg/Cologne/London, 22 December 2020) A phase II clinical trial of a treatment … Continue reading →

Trials 40

Trials Clinical Trials Clinical Trials 40

Drug Discovery World

SEPTEMBER 29, 2023

News round-up for 25-29 September by DDW Digital Content Editor Diana Spencer. The top stories: €27.3M to advance monoclonal antibody for autoimmune diseases AbolerIS Pharma has raised €27.3 million in a Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and Newton Biocapital.

In-Vivo 52

In-Vivo Drugs Antibody Clinical Trials 52

Drug Discovery World

DECEMBER 15, 2023

News round-up for 11-15 December by DDW Digital Content Editor Diana Spencer. New data for relapsed/refractory follicular lymphoma treatment Genmab and AbbVie have announced updated data presented at ASH from the companies’ ongoing Phase I/II EPCORE NHL-1 clinical trial investigating epcoritamab (DuoBody CD3xCD20).

Drugs 52

Drugs Clinical Trials Clinical Trials Manufacturing 52

BioTech 365

DECEMBER 4, 2020

DGAP-News: APEIRON Biologics AG / Key word(s): Study 04.12.2020 / 09:00 The issuer is solely responsible for the content of this announcement. APEIRON Biologics: Patient recruitment completed in Phase II COVID-19 Clinical Trial of APN01 – Results of the double-blind, … Continue reading →

Clinical Trials 40

Clinical Trials Clinical Trials Trials 40

BioTech 365

DECEMBER 4, 2020

DGAP-News: APEIRON Biologics AG / Key word(s): Study 04.12.2020 / 09:00 The issuer is solely responsible for the content of this announcement. APEIRON Biologics: Patient recruitment completed in Phase II COVID-19 Clinical Trial of APN01 – Results of the double-blind, … Continue reading →

Clinical Trials 40

Clinical Trials Clinical Trials Trials 40

XTalks

JANUARY 29, 2021

Data from Eli Lilly and Company’s (NYSE: LLY) Phase III clinical trial evaluating its monoclonal antibody drugs bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) show that combining the two significantly reduced the risk of COVID-19 hospitalizations and death by 70 percent. percent) compared with 36 events (7.0

Antibody 96

Antibody Clinical Trials Clinical Trials Trials 96

Drug Discovery World

APRIL 21, 2023

News round-up for 16-21 April by DDW Digital Content Editor Diana Spencer. The news stories dominating the headlines this week have been the breaking developments in cancer drug discovery announced at the American Association of Cancer Research (AACR) Annual Meeting, which was held in Florida, US from 14-19 April.

Drugs 52

Drugs Antibody Clinical Trials Clinical Trials 52

Drug Discovery World

AUGUST 26, 2022

News round-up for 21-25 August by DDW Editor Reece Armstrong. A treatment for Monkeypox, spider venom for drug discovery and funding for international start-ups are some of the stories in this week’s news round-up. Bayer to advance Huntington’s Disease gene therapy trial . Covid researchers launch Monkeypox study .

Gene Therapy 52

Gene Therapy Drugs Life Science Gene 52

XTalks

FEBRUARY 22, 2024

“We are encouraged by the FDA’s acceptance of the BLA as we endeavor to make datopotamab deruxtecan the first TROP2-directed ADC approved to treat patients with nonsquamous NSCLC after disease progression on prior systemic therapy,” said Susan Galbraith, executive VP of Oncology R&D at AstraZeneca, in the company’s news release.

Antibody 59

Antibody Clinical Trials Clinical Trials Trials 59

Camargo

JULY 8, 2021

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. At Camargo, we have worked with hundreds of investigators who have found new targets for established drugs. Vice President, Regulatory Operations.

Development 130

Development Bioequivalency Gene Expression Drugs 130

The Pharma Data

JANUARY 10, 2021

The new year began with a fairly low level of clinical trial news. Arcturus Therapeutics got the FDA go-ahead for its Phase II trial of its COVID-19 vaccine candidate ARCT-021. The trial will enroll 600 participants, with 450 receiving ARCT-021 and 150 receiving placebo. Here’s a look.

Gene Therapy 52

Gene Therapy Trials Gene Clinical Trials 52

Drug Discovery World

SEPTEMBER 16, 2022

News round-up for 12-16 September by DDW Digital Content Editor Diana Spencer. A slightly quieter week for news in light of national events in the UK, but the vital work of the international drug discovery community goes on and new discoveries are being made all the time. . New treatment hope for patients with rare tumours .

Drugs 52

Drugs FDA Approval Clinical Trials Clinical Trials 52

Drug Discovery World

JUNE 29, 2023

To mark the occasion, this article summarises the most recent news about the ways drug discovery is improving wellbeing and mental health through innovative new treatments and therapies. Another Phase IIa trial will evaluate LYT-300 in patients with moderate to severe PPD.

Drugs 52

Drugs Trials Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 12, 2020

12 November 2020 — The CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalised with respiratory symptoms of COVID-19 did not meet the primary efficacy endpoint. No new safety signal for Calquence was observed in the trials. No new safety signal for Calquence was observed in the trials.

Trials 52

Trials Clinical Trials Clinical Trials Immune Response 52